127 246

Cited 18 times in

Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial.

Authors
 Jae-Seung Paick  ;  Hyung-Ki Choi  ;  Sae-Chul Kim  ;  Tai-Young Ahn  ;  Je-Jong Kim  ;  Jong-Kwan Park  ;  Kwang-Sung Park  ;  Sung-Won Lee  ;  Sae-Woong Kim  ;  Kwanjin Park  ;  Hyonggi Jung  ;  Nam-Cheol Park 
Citation
 ASIAN JOURNAL OF ANDROLOGY, Vol.10(5) : 791-798, 2008 
Journal Title
 ASIAN JOURNAL OF ANDROLOGY 
ISSN
 1008-682X 
Issue Date
2008
MeSH
Double-Blind Method ; Erectile Dysfunction/drug therapy* ; Humans ; Korea ; Male ; Middle Aged ; Patient Satisfaction ; Phosphodiesterase Inhibitors/administration & dosage* ; Phosphodiesterase Inhibitors/adverse effects ; Placebos ; Pyrimidinones/administration & dosage* ; Pyrimidinones/adverse effects ; Sulfones/administration & dosage* ; Sulfones/adverse effects ; Treatment Outcome
Keywords
erectile dysfunction ; phosphodiesterase ; sildenafil citrate
Abstract
AIM: To evaluate the efficacy and safety of SK3530, a newly developed type 5 phosphodiesterase inhibitor (PDE5I), in Korean men with erectile dysfunction (ED). METHODS: A total of 119 patients were randomized at 10 centers in Korea to receive either SK3530 (50, 100, or 150 mg; n = 89) or placebo (n = 30) taken l h before anticipated sexual activity for an 8-week period. The patients were evaluated at baseline and 4 and 8 weeks after beginning therapy. Efficacy was assessed using the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP), and the Global Assessment Question (GAQ). Safety was analyzed by adverse events, laboratory values and vital signs. RESULTS: At the end of the study, all the primary and secondary efficacy end-points were statistically significantly improved by SK3530 compared with placebo (P<0.05). Of the 89 patients in the treatment arm, 36 (42.3%) achieved normal erectile function after treatment, including six patients with severe ED. Treatment-related adverse events occurred in 32 patients. The most common adverse events were flushing, headache, dizziness and eye redness (10.9%, 7.6%, 2.5% and 2.5%, respectively), and most were mild. Only two patients discontinued treatment during the study period because of adverse events. CONCLUSION: The results of our phase II study have confirmed the efficacy and safety of SK3530 in a broad population of men with ED of various etiologies and severity. The optimal doses in terms of efficacy and safety were determined to be 50 mg and 100 mg, respectively
Files in This Item:
T200805690.pdf Download
DOI
10.1111/j.1745-7262.2008.00422.x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Choi, Hyung Ki(최형기)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/108467
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links